Ista Pharmaceuticals Inc

Ista Pharmaceuticals — Investor Presentation (October 2011)

21 slides from Ista Pharmaceuticals's investor presentation, Oct 18, 2011

  1. Slide 1: The vision to see past tomorrow

    Exhibit 99.1 fen i) arr The vision to see past tomorrow

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement Certain statements contained herein are “forward-looking” statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied

  3. Slide 3: ISTA's Track Record of Success

    ISTA’s Track Record of Success • Obtained 5 Rx eye and allergy product approvals in 6 years – ISTALOL®, VITRASE®, XIBROM™, BEPREVE®, BROMDAY™ • Attained top market share positions • Built deep new product R&D pipeline • Assembled experienced management team, formidable specialty sales force: ~ 330 e

  4. Slide 4: ISTA's Strategic Vision "5 in 5"

    ISTA’s Strategic Vision “5 in 5” • Become one of top 3 branded Rx eye care companies in the U.S. • Achieve #1 or #2 position in each product market • Deliver EPS* of $1.00 by 2013 (based on 50 million shares) • Generate $500 million in revenue in 5 years – Develop products for larger markets • Obtai

  5. Slide 5: ISTA: Strategy for Long-Term Success

    ISTA: Strategy for Long-Term Success Marketed Product Business Products Pipeline Development • PROLENSA™ low- • Acquire marketed products concentration bromfenac• License late stage • REMURA™ for dry eye • T-PRED™ • Strong steroid • BEPOMAX™ nasal spray • Acquire marketed products • BEPOSONE™ combo

  6. Slide 6: Marketed Products Can Drive ISTA to >$300 Million in Annual Revenues

    Marketed Products Can Drive ISTA to >$300 Million in Annual Revenues BROMDAY™ BEPREVE® Once-daily prescription eye Twice-daily prescription drop for postoperative eye drop for ocular inflammation and itching associated with reduction of ocular pain in allergic conjunctivitis patients who have underg

  7. Slide 7: BROMDAY Once-Daily

    BROMDAY™ Once-Daily (bromfenac ophthalmic solution) 0.09% • First and only approved once-daily Rx NSAID – For postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction • Rapid, successful switch from twice-daily XIBROM™ • Market-leading $100+ million

  8. Slide 8: BROMDAY Outlook Strong

    BROMDAY Outlook Strong Market Share Continues to Grow BROMDAY IMS WEEKLY 25 24 23 Generic to 22 XIBROM launched 21 20 19 18 17 16 15 TRX NRX Source –IMS Health Weekly NPAAll – MDs ISTA PHARMACEUTICALS 8

  9. Slide 9: BEPREVE

    BEPREVE ® (bepotastine besilate ophthalmic solution) 1.5% • For ocular itching associated with allergic conjunctivitis U.S. Prescription Allergy Eye Competitors • Launched October 2009 NRx$$ 6/30/11 • $16 million revenues in 2010 Lastacaft BEPREVE 7% • Estimated 2011 U.S. market value: 2% Elestat $7

  10. Slide 10: BEPREVE: YTD TRx Prescription Growth Strong

    BEPREVE ® YTD TRx Prescription Growth Strong BEPREVE TRx Peak Allergy Season On track to at least 35000 double 2010 revenues 30000 25000 20000 15000 10000 5000 0 Source –IMS Health Monthly NPA All – MDs ISTA PHARMACEUTICALS 10

  11. Slide 11: ISTA's Near-Term Product Pipeline

    ISTA’s Near-Term Product Pipeline Key Approvals = Revenue of $500 million by 2015 Candidates* Formulation Phase 1 Phase 2 Phase 3 Exclusivity 3-year Hatch Waxman PROLENSA™ Ocular Inflammation & Pain Pending patents 2024 Low-concentration bromfenac REMURA™ Dry Eye 3-year Hatch Waxman Pending patents

  12. Slide 12: PROLENSA (Low-concentration bromfenac)

    PROLENSA ™ (Low-concentration bromfenac) Positive Phase 3 Study Results Reported Oct. 2011 • Two Studies: 440 patients, 40 sites – 1x daily for 16 days (1 dose prior to cataract surgery, 1 dose day of surgery, 1 dose for 14 days) • Statistically significant results – Met primary outcome: cleared ocu

  13. Slide 13: REMURA for Dry Eye

    REMURA ™ for Dry Eye Phase 3 Studies Fail to Meet Endpoints • Two Phase 3 efficacy studies – 840 patients, 2x daily, 42 days – Co-primary endpoints: • Signs of conjunctival staining measured using Lissamine Green • Symptoms measured using Ocular Surface Disease Index (OSDI) • Highly effective in tre

  14. Slide 14: BEPOMAX Bepotastine Nasal Spray

    BEPOMAX ™ Bepotastine Nasal Spray Positive Phase 2 Study Results Reported April 2011 • 600 patients, multi-sites in Texas – Patients presenting allergic rhinitis caused by Mountain Cedar Pollen – 3 concentrations dosed 2x day for 14 days • Primary outcome: Efficacy of any of the 3 doses of BEPOMAX i

  15. Slide 15: Bromfenac Adjunct for AMD

    Bromfenac Adjunct for AMD Paper Published in Sept 2011 Issue of RETINA • Study suggests bromfenac 0.09% (XIBROM™), administered twice daily may have an additive effect when used with intravitreal ranibizumab (LUCENTIS®) in reducing retinal thickness in neovascular AMD • Reducing the central retinal

  16. Slide 16: ISTA's 2011 Milestones to Drive Shareholder Value

    ISTA's 2011 Milestones to Drive Shareholder Value Product / Candidates Milestone Timing BROMDAY™ Complete switch from XIBROM DONE Q1 Initiate Phase 3 DONE Q2 PROLENSA™ Prelim Phase 3 results DONE Q4 Prelim Phase 3 efficacy results: REMURA™ - WEST study DONE Q3 - EAST study DONE Q4 Bromfenac adjunct

  17. Slide 17: Business Development

    Business Development Become $1 Billion Specialty Pharmaceutical Firm • Rx Eye and Rx Allergy – Acquire marketed or soon-to-be marketed products – License late-stage products – Partner for access to primary care physicians and consumer branding • OTC Eye and Allergy – Acquire OTC business platform –

  18. Slide 18: ISTA: Fast-Growing, Niche Pharmaceutical Company

    ISTA Fast-Growing, Niche Pharmaceutical Company Outlook $175– $190 Net Revenues (in $millions) $157 $111 $83 $59 2007 2008 2009 2010 2011 (F) ISTA PHARMACEUTICALS

  19. Slide 19: ISTA's 2011 Financial Guidance

    ISTA’s 2011 Financial Guidance 2011 Net Revenues $175 -$190 million Gross Margin* 75% -77% R&D* 18% -22% SG&A* 44% -48% Operating Income $13 -$16 million Adjusted Cash Net Income** $13 -$16 million Adjusted Cash EPS** (50 mm shares) $0.26 –$0.32 per share Cash at 12/31/11*** $80 -$90 million Growing

  20. Slide 20: ISTA Pharmaceuticals: On-track to Become Major Specialty Pharma Firm

    ISTA Pharmaceuticals On-track to Become Major Specialty Pharma Firm • Generate $300 million in revenues with current products & pipeline – $1.00 EPS by 2013 • Achieve “5 in 5” – 5 new product approvals in next 5 years – $500 million in annual revenues in 5 years • Become billion dollar specialty pha

  21. Slide 21: ] A Pharmaceuticals”

    ] A Pharmaceuticals” IS

Ista Pharmaceuticals — Investor Presentation (October 2011) on 6ix